DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» MedImmune
MedImmune
The Scientific Organizing Committee Gratefully Acknowledges the Pharmaceutical and Biotechnology Industry for Their Generous Support of WCBP 2019
The Impact of Secondary Innovation on Firm Market Value in the Pharmaceutical Industry
United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
Dyax Corp. 300 Technology Square Cambridge, MA 02139 617 225-2500
2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
An Emerging National Resource for Clinical Research and Your Healthcare Partner in Personalized Medicine Innovation
Immunocore and Medimmune Announce New Collaboration to Conduct Immuno-Oncology Combination Trials in Melanoma
Summit for Clinical Ops Executives
The Future of Biomanufacturing
Medimmune Delivering the Next Wave of Scientific Innovation
Shire: a Focused Global Pharmaceutical Company Focusing on a Bright Future Shire Pharmaceuticals Group Plc the Shire Mission
Medimmune Advancing Science for Better Health
Sensitivity Analyses of Time to Adjudicated Attacks in the N
Large-Scale Isolation of Human Skeletal Muscle Satellite Cells from Post-Mortem Tissue and Development of Quantitative Assays to Evaluate Modulators of Myogenesis
A Phase 2A Randomized, Double-Blind, Placebo-Controlled
Medimmune: Leading the Revolution in Respiratory Medicine with Biologics
Drug Companies Participating in MED-Project Stewardship Plan (February 9, 2017)
The Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Final Report Contents
Top View
Long-Term Open Label Efficacy
Development of Therapeutic Antibodies for the Treatment Of
2018 MED-Project Annual Report
Introducing the IMED Biotech Unit
Welcome to Drug Discovery 2019
Immunocore Starts Clinical Trial with Imcgp100 in Combination with Medimmune Immunotherapies Durvalumab and Tremelimumab
Insights Into University-Industry Interactions from the Cambridge Biomedical Cluster
Western Sky Medical Research (El Paso Institute for Medical Research and Development) Lyndon E
Orphan Drug Designations and Approvals List As of 12‐01‐2014
The National Biennial RCRA Hazardous
2020 CONSORTIUM of MS CENTERS PLATFORM ABSTRACTS Disease Assessment and Management
Shire Pharmaceuticals Group Plc
Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-Up Data from the N-Momentum Trial
Contract Research Organizations in the Face of Economic Downturn
Pharma/Biotech M&A
2013 Design Forecast
CONNECTIONS Bringing the Bioscience Community Together with Critical Resources
In the United States District Court for the District of Delaware